Preprint
Article

This version is not peer-reviewed.

Quality of Life Following Treatment for Cervical and Endometrial Cancer: A Patient-Reported EORTC Analysis from Slovakia

Submitted:

12 November 2026

Posted:

13 November 2026

You are already at the latest version

Abstract
Background: Cervical and endometrial cancers remain major public health concerns, and their treatment can substantially affect quality of life (QoL) and survivorship outcomes. This study evaluated QoL among Slovak women after treatment for cervical and endometrial cancer and explored factors associated with post-treatment well-being. Methods: This cross-sectional patient-reported outcome study included 127 women: 74 with endometrial cancer and 53 with cervical cancer. Participants completed a one-time assessment using the EORTC QLQ-C30 together with the disease-specific QLQ-EN24 or QLQ-CX24 modules. Disease stages ranged from IA2 to IIIC1 in cervical cancer and IA to IIIC2ii in endometrial cancer. Eligible participants had histologically confirmed malignancy, ECOG 1–2, and had completed primary treatment 6–60 months before assessment. Analyses included Mann–Whitney U tests, Friedman’s ANOVA, and exploratory multiple linear regression; p-values were interpreted as nominal. Results: The mean age was 57.6 years for endometrial and 49.1 years for cervical cancer patients. All patients underwent surgery; 41.7% received no adjuvant chemotherapy or radiotherapy, 8.7% received adjuvant chemotherapy alone, 24.4% radiotherapy alone, and 25.2% combined chemoradiotherapy. In cervical cancer, cognitive and emotional functioning were relatively preserved, while fatigue, financial difficulties, and sexual/vaginal problems were prominent. In endometrial cancer, cognitive and physical functioning were relatively preserved, whereas social functioning was lower and insomnia and fatigue were frequently reported. Exploratory unadjusted treatment comparisons showed lower global health/QoL among endometrial cancer patients exposed to chemotherapy (r_rb = −0.688, 95% CI −0.950 to −0.387, p < 0.001), whereas radiotherapy exposure was associated with lower cognitive functioning (r_rb = −0.332, 95% CI −0.556 to −0.096, p = 0.008) and higher lymphoedema scores (r_rb = 0.357, 95% CI 0.118 to 0.581, p = 0.005). Cervical cancer treatment comparisons showed mixed, bidirectional symptom associations. In multivariable analyses, the cervical cancer model showed an adjusted R2 of 0.406; increasing age (B = −1.545, 95% CI −2.406 to −0.683, p < 0.001), higher education level (B = −21.706, 95% CI −37.018 to −6.393, p = 0.006), and chemotherapy exposure (B = −43.431, 95% CI −63.459 to −23.403, p < 0.001) were inversely associated with global health/QoL, whereas radiotherapy showed a positive association (B = 46.694, 95% CI 25.199 to 68.189, p < 0.001). In endometrial cancer, chemotherapy (B = −15.121, 95% CI −22.580 to −7.663, p < 0.001) and radiotherapy (B = −7.360, 95% CI −13.715 to −1.005, p = 0.024) were inversely associated with global health/QoL, while rural residence showed a positive association (B = 7.186, 95% CI 0.460 to 13.913, p = 0.037); age was not significantly associated with QoL. These findings remain exploratory and should not be interpreted as causal treatment effects. Conclusions: Women assessed 6–60 months after treatment reported difficulties particularly in fatigue, social functioning, and sexual-health domains. Treatment-related associations should be interpreted cautiously because of treatment-group heterogeneity, potential confounding by indication, and multiple testing. These preliminary findings support further evaluation of survivorship needs related to symptom management, psychosocial support, sexual health, and long-term QoL.
Keywords: 
;  ;  ;  ;  ;  ;  
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.